Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic RetinopathyFARMINGTON HILLS, Mich., Oct. 06, 2023 (GLOBE NEWSWIRE) Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring results from the ZETA-1 Phase 2 Trial of APX3330 at the 23rd Euretina Congress to take plac
PROMISE Technology Launches Pegasus R12 at IBC 2023 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
THE WOODLANDS, Texas, Aug. 21, 2023 Lexicon Pharmaceuticals, Inc. today announced that analyses of clinical study results relating to INPEFA™ , its recently approved drug for heart.
THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug